Baumal Caroline
Transaction: 05/14/2026
SELL
Change
-37,000
Price
$66.30
Filing
05/14/2026
Type
SELL
Apellis Pharmaceuticals, Inc.
APLS • Biotechnology
$41.03
— 0.00 (0.00%)
Current price
EarningsLatest report: Mar 31, 2026
HIGHER-RISK PROFILECautionConfidence: 70%
Quantitative profile — not an investment recommendation.
Quantitative profile — not an investment recommendation.Methodology
Analysis thesis: Caution is warranted. Recent ratios show weaknesses that may limit returns unless fundamentals improve.
Market Cap
$5.25B
Growth
—
Cash Flow
1/5
Trend
Volatile
Evidence
Positive revenue growth · 78.3%Positive free cash flow · 0.36Healthy liquidity · 3.14Expensive earnings multiple · 141.4
Financial data as of: Mar 31, 2026, 12:00 AM UTCLast earnings update: May 7, 2026, 12:00 AM UTCLast profile update: Aug 5, 2026, 2:27 PM UTC
Company Snapshot
Key valuation, quality, financial strength, momentum and analyst data.
Price$41.03
Change0.00%
Market Cap$5.25B
52W Range16.61 - 41.14
Beta-0.25
Gross Margin89.81%
Oper. Margin5.52%
Profit Margin2.23%
Debt/Eq1.31
Current Ratio3.14
Quick Ratio2.70
Target$33.40
Price$41.03
Change0.00%
Market Cap$5.25B
52W Range16.61 - 41.14
Beta-0.25
Gross Margin89.81%
Oper. Margin5.52%
Profit Margin2.23%
Debt/Eq1.31
Current Ratio3.14
Quick Ratio2.70
Target$33.40
Target Upside-18.60%
Target Median$35.00
Target Range19.00 - 48.00
Volume28.64M
Avg Volume6.37M
EPS Surprise0.53
Investment DNA
How strong this company looks for long-term investors
53
out of 100
Business Quality
Margins, moat, returns
41/100
Financial Strength
Debt, cash, stability
65/100
Growth Potential
Revenue and expansion
95/100
Price Attractiveness
Cheap or expensive today
34/100
Why this score▼
Positive revenue growth · 78.3%Positive free cash flow · 0.36Healthy liquidity · 3.14Expensive earnings multiple · 141.4
Analyst view
Analyst sentiment and price target
Analyst sentiment
No vote count available
Bullish
0
Hold
0
Bearish
0
Price Target
2026-06-05
Low
$19.00
Mean
$33.40
Median
$35.00
High
$48.00
Insider Transactions
Recent executive and insider activity
⚠ 3 high-volume insider sells detected
Baumal Caroline
Transaction: 05/14/2026
SELL
Change
-86,525
Price
$0.00
Filing
05/14/2026
Type
SELL
Francois Cedric
Transaction: 05/14/2026
SELL
Change
-273,779
Price
$13.85
Filing
05/14/2026
Type
SELL
| Insider | Type | Change | Price | Transaction | Filing |
|---|---|---|---|---|---|
| Baumal Caroline | SELL | -37,000 | $66.30 | 05/14/2026 | 05/14/2026 |
| Baumal Caroline | SELL | -86,525 | $0.00 | 05/14/2026 | 05/14/2026 |
| Francois Cedric | SELL | -273,779 | $13.85 | 05/14/2026 | 05/14/2026 |
| Francois Cedric | SELL | -195,952 | Not reported | 05/14/2026 | 05/14/2026 |
| Watson David O. | SELL | -34,533 | $66.30 | 05/14/2026 | 05/14/2026 |
| Watson David O. | SELL | -50,136 | $4.00 | 05/14/2026 | 05/14/2026 |
| WHEELER CRAIG A | SELL | -24,444 | $4.00 | 05/14/2026 | 05/14/2026 |
| WHEELER CRAIG A | SELL | -28,195 | $18.20 | 05/14/2026 | 05/14/2026 |
| Boucher Kelley | SELL | -67,396 | $19.39 | 05/14/2026 | 05/14/2026 |
| Boucher Kelley | SELL | -30,146 | Not reported | 05/14/2026 | 05/14/2026 |
| O'Brien Stephanie Monaghan | SELL | -5,750 | $4.00 | 05/14/2026 | 05/14/2026 |
| O'Brien Stephanie Monaghan | SELL | -27,600 | $57.20 | 05/14/2026 | 05/14/2026 |
| DeLong Mark Jeffrey | SELL | -24,666 | $66.30 | 05/14/2026 | 05/14/2026 |
| DeLong Mark Jeffrey | SELL | -114,591 | $4.00 | 05/14/2026 | 05/14/2026 |
| Walbert Keli | SELL | -17,051 | $0.00 | 05/14/2026 | 05/14/2026 |
| Walbert Keli | SELL | -14,684 | $25.12 | 05/14/2026 | 05/14/2026 |
| Nicholson Nur | SELL | -28,367 | $66.30 | 05/14/2026 | 05/14/2026 |
| Nicholson Nur | SELL | -45,220 | Not reported | 05/14/2026 | 05/14/2026 |
| Chan Gerald | SELL | -5,748 | $59.86 | 05/14/2026 | 05/14/2026 |
| Chan Gerald | SELL | -25,666 | $0.00 | 05/14/2026 | 05/14/2026 |